Harbin Pharmaceutical Group Co Ltd banner

Harbin Pharmaceutical Group Co Ltd
SSE:600664

Watchlist Manager
Harbin Pharmaceutical Group Co Ltd Logo
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Watchlist
Price: 3.45 CNY -1.99%
Market Cap: ¥8.7B

Harbin Pharmaceutical Group Co Ltd
Investor Relations

Founded amidst the industrial boom of the 1950s, Harbin Pharmaceutical Group Co., Ltd. has evolved into one of China's pharmaceutical giants, headquartered in Harbin, Heilongjiang Province. Historically grounded in traditional Chinese medicine, it has grown into a multifaceted enterprise that blends its cultural heritage with modern pharmaceutical science. Harbin Pharma's journey from its humble beginnings to becoming a household name is marked by its robust research and development efforts, which are key to its operations. The company's vertical integration strategy stretches through the entire pharmaceutical value chain, encompassing research, production, and distribution, thereby optimizing efficiency and maintaining quality control across its vast product lines. This structure not only helps minimize costs but also allows Harbin Pharma to quickly adapt to changes in the healthcare market.

The company primarily generates revenue through the production and sale of both prescription and over-the-counter drugs, catering to a diverse array of health needs globally. A significant portion of its income stems from the manufacture of antibiotics, patent drugs, and biological products, though it also maintains a strong presence in the consumer health sector with vitamins and dietary supplements. Strategically, Harbin Pharma leverages its extensive distribution network, one of the largest in China, ensuring that its products reach even the most remote areas. Moreover, the company benefits from partnerships and collaborations with international pharmaceutical companies, which allow it to expand its global footprint and enhance its product offerings. In essence, Harbin Pharmaceutical Group's success is anchored in its adaptive business strategies, commitment to innovation, and ability to navigate the complexities of the rapidly evolving pharmaceutical landscape.

Show more
Loading
600664
Shanghai Composite
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Bo Jiang
CFO & VP
No Bio Available
Mr. Xiaodong Meng
VP & Secretary
No Bio Available
Mr. Bangdong Li
Vice President
No Bio Available

Contacts

Address
HEILONGJIANG
Harbin
No. 7 Qunli Avenue, Daoli District
Contacts
+8645151870077
www.hayao.com